Literature DB >> 10835109

Design and synthesis of germline-based hemi-humanized single-chain Fv against the CD18 surface antigen.

C Caldas1, V P Coelho, D J Rigden, G Neschich, A M Moro, M M Brígido.   

Abstract

The 6.7 murine monoclonal antibody (mAb) recognizes the human CD18 antigen and is therefore of interest as an anti-inflammatory agent. The 6.7 heavy variable chain (VH) was humanized using the closest human germline sequence as the template on to which to graft the murine complementary determining regions (CDRs). Two versions were proposed, one in which the residue proline 45 of the murine form was maintained and another in which this framework residue was changed to the leucine found in the human sequence. These VH humanized versions were expressed in the yeast Pichia pastoris as hemi-humanized single-chain Fv (scFvs), with the VL from the murine antibody. The scFv from the murine antibody was also expressed. The binding activities of the murine and both hemi-humanized scFvs were determined by flow cytometry analysis. All the constructions were able to recognize human lymphocytes harboring CD18, indicating successful humanization with transfer of the original binding capability. Some differences between the two hemi-humanized versions were observed. The method used was simple and straightforward, with no need for refined structural analyses and could be used for the humanization of other antibodies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10835109     DOI: 10.1093/protein/13.5.353

Source DB:  PubMed          Journal:  Protein Eng        ISSN: 0269-2139


  6 in total

1.  STING Millennium: A web-based suite of programs for comprehensive and simultaneous analysis of protein structure and sequence.

Authors:  Goran Neshich; Roberto C Togawa; Adauto L Mancini; Paula R Kuser; Michel E B Yamagishi; Georgios Pappas; Wellington V Torres; Tharsis Fonseca e Campos; Leonardo L Ferreira; Fabio M Luna; Adilton G Oliveira; Ronald T Miura; Marcus K Inoue; Luiz G Horita; Dimas F de Souza; Fabiana Dominiquini; Alexandre Alvaro; Cleber S Lima; Fabio O Ogawa; Gabriel B Gomes; Juliana F Palandrani; Gabriela F dos Santos; Esther M de Freitas; Amanda R Mattiuz; Ivan C Costa; Celso L de Almeida; Savio Souza; Christian Baudet; Roberto H Higa
Journal:  Nucleic Acids Res       Date:  2003-07-01       Impact factor: 16.971

Review 2.  Recombinant antibodies for the diagnosis and treatment of cancer.

Authors:  Jürgen Krauss
Journal:  Mol Biotechnol       Date:  2003-09       Impact factor: 2.695

3.  Comparison of humanized IgG and FvFc anti-CD3 monoclonal antibodies expressed in CHO cells.

Authors:  Flavia Serpieri; Andre Inocencio; Jose Marcelino de Oliveira; Alécio A Pimenta; Angélica Garbuio; Jorge Kalil; Marcelo M Brigido; Ana Maria Moro
Journal:  Mol Biotechnol       Date:  2010-07       Impact factor: 2.695

4.  Cloning and expression of an anti-LDL(-) single-chain variable fragment, and its inhibitory effect on experimental atherosclerosis.

Authors:  Soraya M Kazuma; Marcela F Cavalcante; Andréia E R Telles; Andrea Queiroz Maranhão; Dulcineia S P Abdalla
Journal:  MAbs       Date:  2013-07-25       Impact factor: 5.857

5.  Dendritic cells transfected with scFv from Mab 7.B12 mimicking original antigen gp43 induces protection against experimental Paracoccidioidomycosis.

Authors:  Karen S Ferreira; Andrea Q Maranhão; Maria C C Garcia; Marcelo M Brígido; Suelen S Santos; José D Lopes; Sandro R Almeida
Journal:  PLoS One       Date:  2011-01-07       Impact factor: 3.240

6.  Development and characterization of recombinant antibody fragments that recognize and neutralize in vitro Stx2 toxin from Shiga toxin-producing Escherichia coli.

Authors:  Daniela Luz; Gang Chen; Andrea Q Maranhão; Leticia B Rocha; Sachdev Sidhu; Roxane M F Piazza
Journal:  PLoS One       Date:  2015-03-19       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.